Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Total revenue $ 6,752 $ 648 $ 8,601 $ 2,575
Operating expenses:        
Research and development 8,290 2,522 22,640 4,829
General and administrative 3,538 3,996 10,165 8,233
Total operating expenses 11,828 6,518 32,805 13,062
Loss from operations 5,076 5,870 24,204 10,487
Interest and other income, net 107 1 307 2
Interest expense (279) (107) (672) (752)
Change in fair value of warrant liabilities 4 (272) 916 (269)
Loss on conversion of notes 0 (4,719) 0 (4,719)
Net loss 5,244 10,967 23,653 16,225
Deemed dividends on preferred stock 0 (138) 0 (958)
Net loss attributable to common shareholders $ 5,244 $ 11,105 $ 23,653 $ 17,183
Net loss per share attributable to common shareholders:        
Basic and diluted $ 0.19 $ 0.62 $ 0.87 $ 2.75
Weighted average number of shares used in net loss per share calculations:        
Basic and diluted 27,680,307 17,925,585 27,246,667 6,241,947
Net loss attributable to common shareholders $ 5,244 $ 11,105 $ 23,653 $ 17,183
Other comprehensive loss:        
Unrealized gain (loss) on available-for-sale securities 0 0 0 0
Comprehensive loss 5,244 11,105 23,653 17,183
Research And Development Revenue        
Total revenue 2,031 648 3,206 2,408
Grant        
Total revenue $ 4,721 $ 0 $ 5,395 $ 167